Cited 6 times since 2014 (0.6 per year) source: EuropePMC European journal of cancer (Oxford, England : 1990), Volume 50, Issue 7, 28 4 2014, Pages 1399-1401 High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib. Kuiper JL, Heideman DA, Thunnissen E, van Wijk AW, Postmus PE, Smit EF